Neutralizing activity to SARS-CoV-2 of convalescent and control plasma used in a randomized controlled trial.
FFP transfusion
immunology (other than RBC serology)
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
28
12
2020
received:
24
11
2020
accepted:
28
12
2020
pubmed:
16
1
2021
medline:
18
5
2021
entrez:
15
1
2021
Statut:
ppublish
Résumé
There are limited data on the neutralizing activity of convalescent plasma (CP) administered in randomized controlled trials (RCT) of COVID-19 infection. As part of an RCT, CP was collected per FDA guidelines from individuals recovered from COVID-19 infection. CP donors had to have ≥145 optical density (OD) units (ideal target ≥300) using a semiquantitative, immunochromatographic test for IgG antibody to the nucleocapsid protein (NP) of SARS-CoV-2 (typical range 0-500 OD units). A random subset of samples [14 control plasma, 12 CP "medium-anti-NP" (145-299 OD units), and 13 CP "high" anti-NP (≥300 OD units)] were tested for neutralizing antibodies using an established viral luciferase antibody inhibition assay to detect the infection of SARS-CoV-2 pseudovirus that encoded spike protein (SARS2-S The uptake of SARS-CoV-2 pseudovirus by 293T Plasma from donors screened using an immunochromatographic test for IgG antibody to SARS-CoV-2 NP exhibited neutralizing activity meeting FDA's minimum standard in all randomly selected COVID-19 CP units.
Sections du résumé
BACKGROUND
There are limited data on the neutralizing activity of convalescent plasma (CP) administered in randomized controlled trials (RCT) of COVID-19 infection.
STUDY DESIGN AND METHODS
As part of an RCT, CP was collected per FDA guidelines from individuals recovered from COVID-19 infection. CP donors had to have ≥145 optical density (OD) units (ideal target ≥300) using a semiquantitative, immunochromatographic test for IgG antibody to the nucleocapsid protein (NP) of SARS-CoV-2 (typical range 0-500 OD units). A random subset of samples [14 control plasma, 12 CP "medium-anti-NP" (145-299 OD units), and 13 CP "high" anti-NP (≥300 OD units)] were tested for neutralizing antibodies using an established viral luciferase antibody inhibition assay to detect the infection of SARS-CoV-2 pseudovirus that encoded spike protein (SARS2-S
RESULTS
The uptake of SARS-CoV-2 pseudovirus by 293T
DISCUSSION
Plasma from donors screened using an immunochromatographic test for IgG antibody to SARS-CoV-2 NP exhibited neutralizing activity meeting FDA's minimum standard in all randomly selected COVID-19 CP units.
Identifiants
pubmed: 33448402
doi: 10.1111/trf.16283
pmc: PMC8014203
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1363-1369Informations de copyright
© 2021 AABB.
Références
J Exp Med. 2020 Nov 2;217(11):
pubmed: 32692348
Clin Infect Dis. 2021 Sep 7;73(5):e1208-e1211
pubmed: 33270134
J Infect Dis. 2015 Jan 1;211(1):80-90
pubmed: 25030060
Methods Mol Biol. 2009;485:395-405
pubmed: 19020839
N Engl J Med. 2021 Feb 11;384(6):533-540
pubmed: 33369366
Nat Commun. 2020 Aug 13;11(1):4059
pubmed: 32792628
Nat Commun. 2020 Oct 15;11(1):5214
pubmed: 33060595
Autoimmun Rev. 2020 Jul;19(7):102554
pubmed: 32380316
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
Cell. 2020 Oct 29;183(3):739-751.e8
pubmed: 32991842
Viruses. 2020 May 06;12(5):
pubmed: 32384820
Front Immunol. 2020 Oct 16;11:586984
pubmed: 33178220
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
N Engl J Med. 2020 Jun 11;382(24):2302-2315
pubmed: 32289214
Transfusion. 2021 May;61(5):1363-1369
pubmed: 33448402
Rev Med Virol. 2018 Jan;28(1):
pubmed: 29218769
BMJ. 2020 Oct 22;371:m3939
pubmed: 33093056
Genes Dis. 2020 Dec;7(4):551-557
pubmed: 32837985
JAMA. 2020 Aug 4;324(5):460-470
pubmed: 32492084